35. The nanoparticle of claim **31** wherein, in the second polymer, the phenylboronic acid is a nitrophenylboronic acid.

36. The nanoparticle of claim **35**, wherein the second polymer has the structure:



and isomers thereof wherein:

(a) the PEG moiety is attached to the phenyl ring in an ortho or a para position relative to the boronic acid moiety, and/or

(b) the nitro group is attached to the phenyl ring in an ortho or a para position relative to the boronic acid moiety; and

wherein s is from 20-300, and

functional group 2 comprises the first therapeutic agent.

37. The nanoparticle of claim **31**, wherein the first therapeutic agent is a protein.

38. The nanoparticle of claim **37**, wherein the protein is an antibody.

39. The nanoparticle of claim **38**, wherein the antibody is Herceptin®.

40. The nanoparticle of claim **31**, wherein the second therapeutic agent is a small molecule chemotherapeutic.

41. The nanoparticle of claim **40**, wherein the small molecule chemotherapeutic is selected from the group consisting of camptothecin, a camptothecin-based drug, an epothilone and a taxane.

42. The nanoparticle of claim **41**, wherein the small molecule chemotherapeutic is a camptothecin-based drug.

43. The nanoparticle of claim **40**, wherein the small molecule chemotherapeutic is attached to the first polymer through a biodegradable ester bond.

44. The nanoparticle of claim **31**, wherein:

(a) the first polymer comprises a mucic acid-containing polymer coupled to a nitrophenylboronic acid-containing polymer;

(b) the first therapeutic agent is Herceptin®; and

(c) the second therapeutic agent is a camptothecin-based drug.

45. A pharmaceutical composition comprising the nanoparticle of claim **31** and a pharmaceutically acceptable vehicle, excipient or diluent.

46. A pharmaceutical composition comprising the nanoparticle of claim **44** and a pharmaceutically acceptable vehicle, excipient or diluent.

47. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **31** to the subject.

48. The method of claim **47**, wherein the disease, disorder or condition is cancer.

49. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **44** to the subject.

50. The method of claim **49**, wherein the disease, disorder or condition is cancer.

51. The nanoparticle of claim **31**, further comprising a ligand for a cellular receptor.

52. The nanoparticle of **51**, wherein the ligand for a cellular receptor is a protein.

53. The nanoparticle of claim **52**, wherein the ligand for a cellular receptor comprises transferrin.

54. The nanoparticle of claim **51**, wherein:

(a) the first polymer comprises a mucic acid-containing polymer coupled to a nitrophenylboronic acid-containing polymer;

(b) the first therapeutic agent is Herceptin®;

(c) the second therapeutic agent is a camptothecin-based drug; and

(d) the ligand for a cellular comprises transferrin.

55. A pharmaceutical composition comprising the nanoparticle of claim **51** and a pharmaceutically acceptable vehicle, excipient or diluent.

56. A pharmaceutical composition comprising the nanoparticle of claim **54** and a pharmaceutically acceptable vehicle, excipient or diluent.

57. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **51** to the subject.

58. The method of claim **57**, wherein the disease, disorder or condition is cancer.

59. A method for treating a disease, disorder or condition in a subject, the method comprising administering the nanoparticle of claim **54** to the subject.

60. The method of claim **59**, wherein the disease, disorder or condition is cancer.

* * * * *